Moderna (MRNA) Misses Q3 EPS by 16c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates
October 29, 2020 7:00 AM EDTPhase 3 study of COVID-19 vaccine candidate (mRNA-1273) fully enrolled with 30,000 participants, including 37% from diverse communities and 42% at high-risk of severe disease (>65 years or co-morbid risk factors)
Positive interim data from Phase 2 study of CMV vaccine candidate (mRNA-1647) announced during R&D Day; pivotal Phase 3 trial expected to begin in 2021
Received $1.1 billion of customer deposits for supply of mRNA-1273 in Q3 2020, recorded as deferred revenue
CAMBRIDGE, Mass.--(BUSINESS... More
